The impact of VKORCI-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis h North India: A pilot study

Background: The dose requirements for oral anticoagulants in thromboembolic events are influenced by promoter polymorphism in the VKORC 1 gene. However, limited data are available on the influence of the polymorphism in various Indian populations. The present study aimed at determining the relations...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of human genetics 2011-05, Vol.17, p.54-57
Main Authors: Rathore, S S, Agarwal, S K, Pande, S, Mittal, T, Mittal, B
Format: Article
Language:English
Subjects:
Anticoagulants
Data processing
Drugs
Enzymes
Epoxides
Gene frequency
Gene polymorphism
Polymerase chain reaction
Population genetics
Population studies
Prophylaxis
reductase
Restriction fragment length polymorphism
Surgery
Thromboembolism
Vitamin K
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The dose requirements for oral anticoagulants in thromboembolic events are influenced by promoter polymorphism in the VKORC 1 gene. However, limited data are available on the influence of the polymorphism in various Indian populations. The present study aimed at determining the relationship between the VKORC 1-1639 G>A genotypes and maintenance doses of oral anticoagulants for therapeutically stable INR values in patients taking Acitrom after valve replacement surgery. Materials and Methods: Fifty patients from the northem Indian region were genotyped for VKORC 1-1639 G>A by polymerase chain reaction and restriction fragment length polymorphism. Means of the weight-normalized daily Acitrom dose were calculated for every patient. Results and Discussion: The VKORC1 - 1639G>A minor allele frequency in the study population (n = 50) was found to be 22%. The patients with a wild type genotype required the maximum drug dose as suggested for full functionality of the enzyme. Heterozygous patients were found to have an intermediate drug dose and the patients with a variant homozygous genotype had the minimum maintenance drug dose requirement. These findings are in concurrence with the effect of the promoter polymorphism on vitamin K epoxide reductase activity. Conclusion: The VKORC 1-1639 G>A status can be indicative of establishing the therapeutic dose of oral anticoagulants in Indian patients.
ISSN:0971-6866
DOI:10.4103/0971-6866.80360